Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Immunological and Autoimmune Disorders

pharma-news-for-eisai-merck-verona-astrazeneca

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR  EU CHMP Recommendation;  Verona Pharma’s  Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval

Explore More...
stelara-biosimilar-wezlana

Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara

Pharma News for Sanofi, Sosei, AstraZeneca, Arcturus

Dupixent Significantly Reduced COPD Exacerbations; Sosei Heptares to Regain Ownership of GSK4381406; AstraZeneca Gains Rights to Usynova’s KRAS Inhibitor; FDA Approvs OGSIVEO for Desmoid Tumors; Orphan Drug Designation for ARCT-032 for the Cystic Fibrosis; FDA Fast Track Designation for ADP101 for Food Allergies

Pharma News for Takeda, AskBio, Bayer, Lipella

Takeda’s ADZYNMA Approved by FDA; AskBio Presents Preliminary Data from Phase I Trial of Gene Therapy for CHF; Bayer’s Aflibercept 8 mg Recommended for Approval in EU; FDA Orphan Drug Designation to MAIA Biotechnology’s THIO; First Patient Dosed in Phase III ProstACT GLOBAL Study; FDA Grants Orphan Designation for Lipella’s LP-310 Drug Candidate

Pharma News for Pfizer, UCB, BioMarin

FDA Approves PENBRAYA for Most Common Serogroups Causing Meningococcal Disease; BIMZELX Approved Moderate to Severe Plaque Psoriasis; FDA Approves BioMarin’s VOXZOGO; FDA Fast Track Designation to ANPD001 for Parkinson’s Disease; UCB Announces FDA Approval of ZILBRYSQ; EMA Granted Orphan Drug Designation to Lisata’s LSTA1

Allergy Diagnostics Market Trends

Allergy Diagnostics: Unraveling the Science, Market Trends, and Future Prospects

Immunomodulators Market and Key Applications

Harnessing the Power of Immunomodulators: Applications and Implications

Pharma News for Amgen, Anaptys, Sanofi, Boehringer

Amgen to Acquire Horizon Therapeutics; Sanofi and Teva Announce Collaboration; Boehringer Obesity Drug Trial Update; FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL; Anaptys Announces Phase 3 Clinical Trial Results of Imsidolimab; Orphan Drug Designation to GC Biopharma’s GC1126A

Pharma News for AbbVie, Novartis, Avenge Bio, Eli Lilly

AbbVie Presents Phase III CANOVA Study Results; Novartis’ Iptacopan Shows Promise in Phase III Study; Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer; FDA Issues Complete Response Letter for Lebrikizumab; Nedosiran Approveed for Primary Hyperoxaluria Type 1; Orphan Drug Designation to BDC-1001 for Gastric Cancers

Pharma News for BMS, Alnylam, MaaT Pharma

BMS’s LPA1 Antagonist; Alnylam’s KARDIA-1 Phase 2 Study; Day One Biopharma Sought FDA Approval for Tovorafenib; EMA Orphan Drug Designation to MaaT Pharma’s MaaT033; Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole + Sertraline; Phase III CheckMate – 227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy

Pharma News for Biogen, Astellas, Ascentage

FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

Nutricosmetics Market Outlook

Evaluating the Evolving Trends in the Nutricosmetics Market: The Intersection of Nutrition and Skincare

graft-versus-host-disease-gvhd-treatment

Graft-Versus-Host Disease (GvHD) Treatment Market: A Moving Target For Therapies

Gene Therapies for Dystrophic Epidermolysis Bullosa

Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Pharma News for Pfizer, Daiichi Sankyo, Kyverna, Servier

Daiichi Sankyo’s Intravenous Iron Replacement Therapy; ANeuroTech’s Adjunctive Anti-depression Drug, ANT-01; Kyverna Therapeutics’s KYV-101 in Lupus Nephritis; Servier Presents Data from Phase 3 INDIGO Trial of Vorasidenib; FDA Approves Pfizer’s ABRYSVO

anca-associated-vasculitis-treatment

ANCA-associated Vasculitis Treatment Market: Unraveling the Complexities

emerging-tlr-7-8-agonists

Role of TLR7/8 Agonists in Treating Various Cancers

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader